Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia.
作者信息
Abouir Kenza, Calmy Alexandra, Lorenzini Kuntheavy Roseline Ing
机构信息
Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.
Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
出版信息
JAMA. 2022 Feb 15;327(7):682-683. doi: 10.1001/jama.2021.24532.
PMID:35166808
Abstract
摘要
相似文献
1
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia.地塞米松与新冠病毒肺炎合并严重低氧血症成年患者无生命支持存活天数
JAMA. 2022 Feb 15;327(7):682-683. doi: 10.1001/jama.2021.24532.
2
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia.地塞米松与新冠病毒肺炎合并严重低氧血症成年患者无生命支持存活天数
JAMA. 2022 Feb 15;327(7):682. doi: 10.1001/jama.2021.24525.
3
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia.地塞米松与COVID-19合并严重低氧血症成人患者无生命支持存活天数的关系
JAMA. 2022 Feb 15;327(7):682. doi: 10.1001/jama.2021.24522.
4
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia-Reply.地塞米松与新冠病毒肺炎合并严重低氧血症成人患者无生命支持存活天数——回复
JAMA. 2022 Feb 15;327(7):683. doi: 10.1001/jama.2021.24535.
5
In COVID-19 with hypoxemia, 12 vs. 6 mg/d of dexamethasone did not increase days alive without life support.在低氧血症的 COVID-19 患者中，12 毫克/天与 6 毫克/天的地塞米松治疗并未增加无需生命支持的存活天数。
Ann Intern Med. 2022 Mar;175(3):JC33. doi: 10.7326/J22-0001. Epub 2022 Mar 1.
6
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.地塞米松 12 毫克与 6 毫克对 COVID-19 合并严重低氧血症成人患者存活无生命支持天数的影响：COVID 类固醇 2 随机试验。
JAMA. 2021 Nov 9;326(18):1807-1817. doi: 10.1001/jama.2021.18295.
7
Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial.
CJEM. 2022 Apr;24(3):266-267. doi: 10.1007/s43678-022-00293-1. Epub 2022 Mar 29.
8
Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia.基于因果贝叶斯机器学习评估 COVID-19 伴严重低氧血症患者地塞米松剂量治疗效果的异质性。
Sci Rep. 2023 Apr 21;13(1):6570. doi: 10.1038/s41598-023-33425-3.
9
Oral dexamethasone for COVID-19 patients at the initial recognition of hypoxia: Can an early dose herald a better outcome?对于初次发现缺氧的新冠患者使用口服地塞米松：早期剂量能否预示更好的结果？
J Microbiol Immunol Infect. 2022 Feb;55(1):170-171. doi: 10.1016/j.jmii.2021.07.016. Epub 2021 Oct 7.
10
Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.地塞米松对住院 COVID-19 患者 SARS-CoV-2 浓度动力学和抗体反应的影响：一项前瞻性观察研究的结果。
Clin Microbiol Infect. 2021 Oct;27(10):1520.e7-1520.e10. doi: 10.1016/j.cmi.2021.06.008. Epub 2021 Jun 15.
引用本文的文献
1
Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia-Post hoc exploratory analyses of the COVID STEROID 2 trial.地塞米松 12 毫克与 6 毫克治疗 COVID-19 伴严重低氧血症患者的疗效差异：COVID 类固醇 2 试验的事后探索性分析。
Acta Anaesthesiol Scand. 2023 Feb;67(2):195-205. doi: 10.1111/aas.14167. Epub 2022 Nov 8.
Zotero 插件